You are here: Industry Insights > MZL

News List

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL PharmaSources
April 20, 2023
April 20, 2023，InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or refractory marginal zone lymphoma, follicular lymphoma expresspharma
February 09, 2021
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics at an IND stage (TGR 1202) in 2012.
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting drugs
June 13, 2019
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting.